Top Story
Clinical TrialsDiscover how Bayer's elinzanetant offers promising relief for vasomotor symptoms in menopausal and breast cancer patients, with significant trial results showing reduced hot flashes and improved sleep.
Latest Stories
Artificial Intelligence
Patient Outcomes & Engagement
Featured Webinars
“S” Stands for Systematic: Demystifying the Systematic Literature Review
Thursday, December 5, 2024
Sponsor: ICON
Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned
Tuesday, September 17, 2024
Sponsor: ICON
Market Access – Transforming BioTech Commercial Decisions?
Thursday, September 5, 2024
Partners: Scientist.com, FingerPost Consulting Ltd
The Scientific and Operational Elegance of Study Replication with Real-World EHR Data: A Vitiligo and Alopecia Example
Thursday, June 13, 2024
Sponsor: Panalgo, LLC
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
01/08/2025 09:32 PM ET
Calidi CLDI -30% AH Offering; Silo Pharma SILO +55% Patent
Due to the US marketing being closed in observance for a day of mourning for former President Jimmy Carter, we will not be sending out our Pre-Market Movers or Daily Updates newsletters on Thursday, January 9, 2025. Calidi Biotherapeutics, Inc. (NYSE: [...]
Read More01/07/2025 09:24 PM ET
Hoth HOTH +178% Phase 2a Data; Sana SANA +234% AH Data
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shared interim safety and efficacy results from its Phase 2a CLEER-001 clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients.100% of patients in cohort [...]
Read More01/06/2025 08:49 PM ET
Predictive POAI +58% Acquired by Renovaro RENB; SciSparc +103% European Patent
Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction. Renovaro will acquire 100% of Predictive Oncology [...]
Read More01/03/2025 05:10 PM ET
Check-Cap CHEK +53% Patent; Bionano BNGO +24% Offering
Bionano Genomics, Inc. (NASDAQ: BNGO) entered into an approximately $10 million registered direct offering agreement with institutional investors for the sale of 39,682,540 shares of common stock and warrants to purchase an equal number of shares at a combined price [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
